Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00050947 · ClinicalTrials.gov registry record · Phase 3

Pediatric Epilepsy Study

A Phase 3 study of Epilepsy, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
94
Enrollment target
20
Study locations

NCT00050947 is a Phase 3 study of Epilepsy that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 94 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00050947, a Phase 3 study of Epilepsy, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
94 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

Conditions Studied

Epilepsy

Interventions

  • DRUG oxcarbazepine

Study Locations (20)

Ohio

  • - Akron
  • - Cincinnati
  • - Cleveland

Alabama

  • - Birmingham
  • - Mobile

California

  • - Madera
  • - Orange

Florida

  • - Miami
  • - Tampa

Minnesota

  • - Duluth
  • - Saint Paul

Missouri

  • - Chesterfields
  • - St Louis

New York

  • - Buffalo
  • - New York

Colorado

  • - Denver

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2002-07
Est. Completion 2004-02
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00050947

The ClinicalTrials.gov registry entry for NCT00050947 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (90% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which oxcarbazepine is the first listed.

NCT00050947 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Ohio, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00050947 about?

NCT00050947 is a clinical study titled "Pediatric Epilepsy Study". This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

What is the current status of trial NCT00050947?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2002-07. Estimated completion is 2004-02.

What conditions does trial NCT00050947 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT00050947?

The interventions under investigation include: oxcarbazepine (DRUG).

Who is sponsoring clinical trial NCT00050947?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00050947 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Epilepsy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.